Harmony Biosciences shares are trading lower after Goldman Sachs downgraded the stock from Neutral to Sell and lowered its price target from $40 to $31.
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs has downgraded Harmony Biosciences from Neutral to Sell and reduced its price target from $40 to $31. This has resulted in a decrease in the trading price of Harmony Biosciences shares.
September 25, 2023 | 2:04 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Harmony Biosciences' stock has been downgraded by Goldman Sachs, leading to a decrease in its trading price.
Goldman Sachs, a major financial institution, has downgraded Harmony Biosciences' stock and lowered its price target. This negative outlook is likely to decrease investor confidence in the stock, leading to a decrease in its trading price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100